In Part 1, we traced ibogaine from its roots in the Bwiti tradition to Howard Lotsof's accidental discovery and decades of suppressed research. Now we cover what's happening right now — and why 2026 may be the year everything changes.
The Stanford Study That Changed the Conversation
In January 2024, a study published in Nature Medicine — one of the most prestigious medical journals in the world — delivered the kind of evidence that politicians and regulators couldn't ignore.
Researchers at Stanford University's Brain Stimulation Lab, led by Kirsten Cherian and Jackob Keynan, studied 30 male Special Operations Forces veterans with predominantly mild traumatic brain injuries (TBI). The protocol, called MISTIC (Magnesium-Ibogaine-Supplemented Therapy In Combatants), combined ibogaine with magnesium co-administration and complementary therapies.
The results were striking:
- Significant improvements in disability scores both immediately after treatment and at one-month follow-up
- Reductions in PTSD, depression, and anxiety symptoms
- No unexpected or serious adverse events
- Magnesium co-administration appeared to help mitigate cardiac risks
The authors emphasized that controlled clinical trials were still needed, but the signal was clear: ibogaine, administered under proper medical supervision with cardiac protections, produced meaningful results in a population that had largely been failed by conventional treatments.
This study became the scientific foundation for everything that followed.
Veterans Leading the Charge
The political momentum behind ibogaine is inseparable from the veteran community. Approximately 22 veterans die by suicide every day in the United States. Many struggle with PTSD, TBI, depression, and opioid addiction that resist conventional treatments — or that the VA system is too overwhelmed to adequately address.
Marcus Capone, a former Navy SEAL who struggled with severe PTSD after his service, traveled to Mexico for ibogaine treatment after exhausting conventional options. He experienced significant improvement and, alongside his wife Amber, founded VETS (Veterans Exploring Treatment Solutions). The organization has funded ibogaine treatments for veterans and become one of the most visible advocacy voices in Washington.
The VETS Act, introduced in Congress with bipartisan support, seeks to study and expand access to ibogaine and other psychedelic treatments for veterans. The veteran suicide crisis has created something rare in modern politics: a cause that unites both parties.
The Executive Order — April 19, 2026
On April 19, 2026, President Trump signed an executive order directing the federal government to study ibogaine as a potential treatment for veterans with PTSD and addiction. This represents the most direct federal endorsement of a psychedelic compound for therapeutic use in American history.
The order was championed by Robert F. Kennedy Jr., serving as Secretary of Health and Human Services, who called ibogaine "the most promising" treatment for depression and mental health conditions. Kennedy has been described as going "all in" on ibogaine research, aligning the full weight of HHS behind studying its therapeutic potential.
For a compound that has been Schedule I since the 1970s, this executive order represents a seismic shift. The federal government isn't just tolerating ibogaine research — it's actively directing it.
FDA Greenlights First Human Clinical Trial — April 25, 2026
Six days after the executive order, the FDA greenlit the first-ever human clinical trial of an ibogaine compound in the United States. This is a historic regulatory milestone — the first time ibogaine has entered the formal FDA clinical trial pathway.
While the specific details of the trial protocol are still emerging, the timing is unmistakable. After decades of Schedule I classification, after NIDA terminated its research in 1995, after thousands of Americans traveled to Mexico and the Bahamas for underground treatments — ibogaine is finally being studied through the official channels that could lead to FDA approval.
Texas Commits $50 Million
In 2025, the state of Texas allocated $50 million for clinical research to develop FDA-approved ibogaine treatments for opioid use disorder and related conditions. Texas — not typically associated with progressive drug policy — recognized that the opioid crisis demanded unconventional solutions, and that the state's large veteran population stood to benefit directly.
This level of state funding for a Schedule I compound would have been unthinkable five years ago.
The Safety Infrastructure Being Built
The single biggest concern with ibogaine has always been safety — specifically cardiac risk. The 38 documented deaths associated with ibogaine treatment make this a non-trivial concern. But the field has learned from those tragedies, and modern protocols look very different from the early days:
- Pre-treatment cardiac screening: EKG/ECG to measure QT interval and rule out heart conditions
- Medical supervision: Licensed physicians present throughout treatment
- Magnesium co-administration: The Stanford MISTIC protocol showed this may protect against cardiac complications
- Lower dosing: Dr. Deborah Mash's research showed better outcomes at 10-12 mg/kg versus the higher doses used in early studies
- Patient screening: Excluding patients with pre-existing cardiac conditions, those on QT-prolonging medications, or liver disease
- Post-treatment monitoring: 24-48 hours of cardiac monitoring during and after the experience
Organizations like the Global Ibogaine Therapy Alliance (GITA) are working to establish standardized safety guidelines and provider training. The goal is to make ibogaine therapy as safe as possible — not to pretend the risks don't exist.
Why Now? The Convergence
Several forces have converged to create this moment:
- The fentanyl crisis: Over 100,000 overdose deaths annually in the US. Existing treatments like methadone and buprenorphine are maintenance-based — patients remain on them indefinitely. Ibogaine offers the possibility of a single treatment that interrupts addiction at a neurological level.
- The veteran suicide crisis: 22 veterans per day. Conventional PTSD treatments are failing too many people.
- The Stanford study: Rigorous clinical evidence in Nature Medicine gave regulators and politicians the scientific cover they needed.
- Political alignment: RFK Jr. at HHS, bipartisan veteran advocacy, and a president willing to sign the executive order.
- The broader psychedelic renaissance: Oregon legalized psilocybin therapy in 2020. Colorado decriminalized psychedelics in 2022. Australia approved MDMA and psilocybin for therapeutic use in 2023. The cultural and regulatory ground has been shifting for years.
What Ibogaine's Story Means for Botanical Medicine
We cover ibogaine on this blog not because we sell it — we don't — but because its story is our story.
A plant used for centuries by indigenous communities. Dismissed and prohibited by Western governments. Studied by scientists who found real therapeutic potential. Scheduled not because of evidence, but because of politics. And now, decades later, finally being reconsidered because the crisis got bad enough that prohibition became indefensible.
Kratom and 7-hydroxymitragynine are on a parallel track. Traditional use in Southeast Asia. Western adoption driven by the opioid crisis. Regulatory battles between prohibition and responsible regulation. The same arguments apply: test it, regulate it, let the science lead, and stop criminalizing plants that people are using to survive.
The 20+ states that have passed Kratom Consumer Protection Acts chose regulation over prohibition. The executive order on ibogaine suggests the federal government may finally be learning the same lesson.
We'll be watching closely.
← Read Part 1: From African Tradition to Accidental Discovery
This article is for educational purposes only. Favor'd Alkz does not sell, distribute, or advocate for ibogaine products. We cover this topic because the regulatory and scientific journey of botanical compounds is central to our industry and our values. These statements have not been evaluated by the FDA.
